Skip to content

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cardiomyopathy, Hypertrophic

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    12 to 17

Participation Criteria

Inclusion Criteria:

* Diagnosis of HCM
* Presence of LVOT obstruction
* Presence of symptoms

Exclusion Criteria:

* Phenocopy diseases resulting in myocardial hypertrophy not related to sarcomere dysfunction
* Evidence of LVEF \<50% in prior 6 months
* Planned escalation in HCM therapy or upcoming intervention (eg, major cardiac surgery, HCM medication dose increase)

Other protocol-defined Inclusion/Exclusion criteria apply.

Study Location

Local Institution - 0046
Local Institution - 0046
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Site 0046

Local Institution - 0041
Local Institution - 0041
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Site 0041

Stollery Children's Hospital
Stollery Children's Hospital
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Jennifer Conway, Site 0041

7804073952
Study Sponsored By
Bristol-Myers Squibb
Participants Required
More Information
Study ID: NCT06253221